Is It Possible to Eliminate Postoperative Shunt Infections?: Results of a Modified Hydrocephalus Clinical Research

Mohammad Elbaroody1, Adham Ezz1, Amr Helmy Eldessouky1

  • 1Department of Neurosurgery, Cairo University, Kasr Alainy Faculty of Medicine, Cairo, Egypt.

Abstract

Insights

A modified Hydrocephalus Clinical Research Network (HCRN) protocol effectively prevented ventriculoperitoneal shunt (VPS) infections in pediatric patients, achieving a 0% infection rate in a retrospective study. Further validation is needed for broader recommendations.

Area of Science:

  • Neurosurgery
  • Pediatric Surgery
  • Infectious Disease Prevention

Background:

  • Postoperative shunt infection poses significant risks in neurosurgery.
  • Existing protocols have reduced, but not eliminated, ventriculoperitoneal shunt (VPS) infections.
  • Preventing VPS infections remains a critical challenge in managing hydrocephalus.

Purpose of the Study:

  • To evaluate the efficacy of a modified Hydrocephalus Clinical Research Network (HCRN) protocol in preventing postoperative shunt infections.
  • To assess the impact of rigid protocol adherence on infection rates in pediatric patients undergoing VPS insertion.
  • To determine the feasibility of a zero-infection rate using the modified protocol.

Main Methods:

  • Retrospective evaluation of pediatric patients with congenital hydrocephalus who underwent VPS insertion.
  • Application of a modified HCRN protocol from June 2019 to January 2020.
  • Follow-up duration ranged from 11 to 24 months.

Main Results:

  • 37 procedures were performed on 37 children (median age 5 months; 25 males).
  • Congenital hydrocephalus was the primary indication for VPS placement in 80% of cases.
  • A 0% shunt infection rate was observed during the mean follow-up period of 19.4 months.

Conclusions:

  • The modified HCRN protocol demonstrated effectiveness in preventing postoperative shunt infections.
  • Preliminary findings suggest this protocol is a promising strategy for reducing shunt infection rates.
  • Larger prospective studies are recommended to validate these results before widespread adoption.